Zoetis Inc. Expands Capabilities of Vetscan OptiCell Hematology Analyzer

Zoetis Inc. (NYSE: ZTS) announced the expansion of its Vetscan OptiCell hematology analyzer, now offering cellular hemoglobin concentration mean (CHCM), making it a first in point-of-care diagnostics. Separately, Citi initiated coverage with a Buy rating and set a price target of $145.

By Noor Ul Ain Rehman May 1, 2026 2 min read · Yahoo Finance · May 1, 2026, 07:57 UTC

Zoetis Inc. Expands Capabilities of Vetscan OptiCell Hematology Analyzer

Tickers: $HSIC $ZTS

Topics: AI animal health diagnostic tools pharma

Read the full article at Yahoo Finance

More World news

Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC
EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures Seeking Alpha · November 12, 2026, 16:50 UTC
Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC